Background-Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a novel marker and participant in vascular inflammation. Inflammation also is associated with coronary atherosclerosis. We tested the hypothesis that local coronary production of Lp-PLA 2 is enhanced in patients with early coronary atherosclerosis and associated with local endothelial function. Methods and Results-Coronary angiography, blood flow, flow reserve, endothelial function assessment, and intravascular ultrasound with volumetric analysis were performed in 15 patients with mild coronary atherosclerosis and in 15 control subjects. Plasma samples were collected simultaneously from the left main coronary artery and coronary sinus for measurement of Lp-PLA 2 , lysophosphatidylcholine (a product of Lp-PLA 2 ), and C-reactive protein. Hemodynamic parameters and cholesterol were similar in both groups. Arterial Lp-PLA 2 levels were similar in patients and control subjects: 225 ng/mL (interquartile range [IQR], 196 to 273 ng/mL) versus 221 ng/mL (IQR, 177 to 294 ng/mL). Lp-PLA 2 net production in the coronary circulation was higher in patients compared with control subjects: 519 ng/min (IQR, 198 to 1276 ng/min) versus Ϫ529 ng/min (IQR, Ϫ872 to Ϫ79 ng/min; Pϭ0.001) and correlated with percent atheroma volume (r s ϭ0.37, Pϭ0.04). Net production of lysophosphatidylcholine was higher in patients compared with control subjects: 199 ng/min (IQR, Ϫ592 to 470 ng/min) versus Ϫ505 ng/min (IQR, Ϫ1119 to 0 ng/min; Pϭ0.03) and correlated with coronary endothelial dysfunction (r s ϭ0.5, Pϭ0.005). C-reactive protein was not significantly different between the groups. Conclusions-Early coronary atherosclerosis in humans is characterized by local production of Lp-PLA 2 . Local coronary production of lysophosphatidylcholine, the active product of Lp-PLA 2 , is associated with endothelial dysfunction. These results support the role for Lp-PLA 2 in the mechanism of regional vascular inflammation and atherosclerosis in humans.
I nflammation has been recognized as a major component in the pathogenesis of atherosclerosis. 1 Inflammation may occur locally in the vessel wall, 2 but signs of inflammation often are found in the systemic circulation. Increased circulating levels of inflammatory biomarkers are found in patients with established coronary artery disease 3 and during acute coronary syndromes. 4 In patients without clinical manifestations of atherosclerosis, levels of inflammatory biomarkers may predict future cardiovascular events. 5 However, in the early stage, coronary atherosclerosis may be associated with a more regional inflammatory process. 6 The increased levels of inflammatory biomarkers in these patients may reflect a direct role of inflammation in the disease process. 7
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In addition to inflammation, an important manifestation of early atherosclerosis is endothelial dysfunction. Endothelial dysfunction is characterized by an imbalance between the endothelium-dependent vasodilator and vasoconstrictor activity, as well as by altered antiinflammatory and anticoagulant properties of the endothelium. 8, 9 In fact, inflammatory mediators may well contribute to endothelial dysfunction in early atherosclerosis. For example, the association between inflammation and endothelial dysfunction may involve the participation of lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ).
Lp-PLA 2 , a member of the phospholipase A 2 family of enzymes, is a 45.4-kDa protein produced by macrophages, T lymphocytes, and mast cells. Recently, we have demonstrated that systemic Lp-PLA 2 levels are associated with coronary endothelial dysfunction independently of other cardiovascular risk factors. 10 Increased systemic levels of Lp-PLA 2 also are an independent predictor of coronary events. 11 Lp-PLA 2 is found in human atherosclerotic plaques 12 and hydrolyzes the sn-2 fatty acids of oxidized phospholipids to yield oxidized fatty acid and lysophosphatidylcholine (lysoPC), which are proinflammatory particles. 10, 13 LysoPC plays an important part in the effect of Lp-PLA 2 on endothelial dysfunction. 14 It causes an increase in oxidative stress, 15 downregulation of endothelial nitric oxide synthase mRNA expression in endothelial cells 14, 16 and inhibition of endothelial cell migration to sites of endothelial damage. 17 Thus, Lp-PLA 2 may play a significant role in early coronary atherosclerosis in humans, mainly through production of lysoPC.
Although circulating inflammatory mediators have been linked to cardiovascular disease, information is lacking on the regional production or extraction of inflammatory markers, especially in the early stage of atherosclerosis. The present study was designed to test the hypothesis that in patients with early coronary atherosclerosis, as determined by intravascular ultrasound, Lp-PLA 2 and lysoPC production increases across the coronary circulation and has local affects on endothelial function.
Methods

Patient Population
The study was approved by the Mayo Clinic Institutional Review Board, and informed consent was obtained. The study group consisted of 30 patients who underwent diagnostic coronary angiography for the evaluation of coronary artery disease and did not have significant epicardial coronary artery stenoses (ie, stenosis Ͻ30%). Patients and control subjects were prospectively defined according to the presence or absence of apparent lesions by angiography and intravascular ultrasound (IVUS). Exclusion criteria included an ejection fraction Ͻ45%; acute coronary syndrome; previous myocardial infarction or cerebrovascular accident within 6 months; previous percutaneous coronary intervention; use of radiographic contrast agents within 12 hours before the study; significant endocrine, hepatic, or renal disorders; local or systemic infectious disease within 4 weeks before the study; inflammatory disease; pregnancy; or lactation. The study was performed after overnight fasting, and medications that could affect coronary vasoreactivity were discontinued for at least 48 hours before the study. All patients gave informed consent before participation.
Study Protocol
The study protocol was performed at the same stage of the diagnostic coronary angiography. Routine blood samples were obtained before the study and included cholesterol and lipoprotein(a) measurements. A 5F multipurpose or amplatz left catheter was introduced percutaneously into the coronary sinus under fluoroscopic guidance via the right femoral vein, 18 and a 6F or 7F guiding catheter was placed in the left main coronary artery. Blood samples for Lp-PLA 2 , lysoPC, and C-reactive protein (CRP) were obtained simultaneously from the coronary sinus and left main coronary artery and were stored at Ϫ80°C until assay.
Lp-PLA 2 mass was measured as previously described with an enzyme-linked immunoassay (PLAC test, diaDexus, Inc, San Francisco, Calif). 10,19 -21 This assay consists of 2 high-affinity monoclonal antibodies to Lp-PLA 2 . The range of detection was 50 to 1000 ng/mL, and the interassay coefficients of variation were 7.8% at 276 ng/mL, 6.1% at 257 ng/mL, and 13.5% at 105 ng/mL. LysoPC was measured with liquid chromatography tandem mass spectrometry with an electrospray triple quadruple mass spectrometry (SCIEX API 3000, AME Bioscience, Concord, Ontario, Canada). Plasma was extracted with butanol after the addition of 17:0 lysoPC as internal standard. The dried-down extract was reconstituted in methanol for analysis with a triple quadruple mass spectrometry (SCIEX API 3000) with a Turbo Ion Spray Source. Chromatographic separation was achieved with a Phenomenex C8 column. Mobile phase consisted of a mixture of methanol (90%), 100 mmol/L ammonium acetate (10%), and formic acid (0.05%). Complete analysis time was 3 minutes with lysoPC eluting at approximately 1.5 minutes. Selective reaction monitoring was used to determine 16:0 lysoPC. Inter-assay CVs were 2.0% at 131 mol/L and 12.0% at 45 mol/L.
Serum CRP concentrations were measured on a Hitachi 912 automated chemistry analyzer using a high-sensitivity polystyrene particle-enhanced immunoturbidimetric assay from DiaSorin (Stillwater, Minn). Intra-assay coefficients of variation are 8.8%, 1.1%, and 0.4% at 0.028, 0.20, and 1.15 mg/dL, respectively. Interassay coefficients of variation were 8.0%, 2.0%, and 1.0% at 0.05, 0.30, and 1.86 mg/dL, respectively.
The gradients of Lp-PLA 2 , lysoPC, and CRP across the coronary circulation were calculated by subtracting the aortic from the coronary sinus concentration. Net production of each substance in the left anterior descending artery territory was then calculated as the gradient times coronary blood flow. 22, 23 After blood samples were obtained, 5000 U heparin was given systemically. For calculating the degree of production of Lp-PLA 2 and CRP, coronary blood flow was assessed. A Doppler guidewire (Flowire, Volcano Therapeutics Inc, Rancho Cordova, Calif) was positioned in the mid portion of the left anterior descending coronary artery, and measured velocities were used to calculate coronary blood flow. Velocity signals were instantaneously obtained from the Doppler wire by an online fast Fourier transform, and average peak velocity was determined. Coronary artery diameter was measured by an independent investigator in the segment 5 mm distal to the tip of the Doppler wire offline with a quantitative coronary angiography program (Medis Corp, Leiden, the Netherlands) as previously described. 24 Coronary blood flow was calculated from the Dopplerderived time velocity integral and vessel diameter as follows: ϫ(coronary artery diameter/2) 2ϫ (average peak velocity/2). 25 Coronary vasoreactivity in response to acetylcholine and coronary flow reserve to adenosine were assessed as previously described. 26, 27 In brief, intracoronary bolus injections of incremental doses (18 to 48 g) of adenosine were administered until maximal hyperemia was achieved or the largest dose was given to evaluate endotheliumindependent microvascular coronary flow reserve. Coronary flow reserve was calculated by dividing the average peak velocity after adenosine injection by the average peak velocity at baseline.
Subsequently, to assess endothelium-dependent vasoreactivity, acetylcholine at increasing concentrations (10 Ϫ6 , 10 Ϫ5 , and 10 Ϫ4 mol/L) was selectively infused for 3 minutes at each concentration into the left anterior descending coronary artery. 26, 27 After the assessment of coronary flow reserve and coronary endothelial function, 200 g nitroglycerin IC was given, and IVUS imaging was performed according to previously described methods. 28 A 2.9F IVUS catheter with electronic scanning (Volcano Therapeutics Inc) was inserted into the mid distal left anterior descending artery, and a motorized pullback system at a speed of 0.5 mm/s was used. During pullback, images were obtained at 30 frames per second and were stored digitally on a CD-ROM for later offline 3-dimensional volumetric IVUS analysis. The volumetric IVUS analyses were performed from the distal left anterior descending coronary artery to the left anterior descending coronary artery ostium with customized software (echoPlaque 2, version 2.5, INDEC Systems Inc, Santa Clara, Calif) by an examiner unaware of the clinical characteristics of the patients. 29 Manual contour detection of the lumen and the media-adventitia interface was performed in accordance with the standards of the American College of Cardiology. 30 The external elastic membrane and lumen areas were measured in cross sections spaced 0.8 mm apart. Atheroma area was calculated as external elastic membrane area minus luminal area. Volumes were calculated according to the Simpson rule as mean atheroma area multiplied by pullback length in millimeters. To compensate for differences in length of the studied vessels segment, each measured volume was normalized to 10 mm of length (volumes divided by the examined segment length and multiplied by 10). The percent atheroma volume was computed as follows: ⌺ atheroma areaϫ100 /⌺ external elastic membrane area. 31 Endothelial dysfunction was defined as any decrease in coronary artery diameter in response to acetylcholine.
Data Analysis
Continuous variables are presented as meanϮSEM or median and interquartile range (IQR) and dichotomous variables as values and percentages. The baseline characteristics of groups and biomarkers levels were compared by the Wilcoxon rank-sum test for continuous variables and by Pearson's 2 statistic for categorical variables. Single predictor and multivariable linear regression models were used to calculate the association between CRP or Lp-PLA 2 net production and plaque volume. Variables found to show marginal association with net production in the single predictor analysis (PϽ0.20) were used in the multivariable model. Because of the known association between low-density lipoprotein (LDL) and Lp-PLA 2 , LDL levels were added to the model. Pearson's correlation coefficient and the nonparametric Spearman's correlation methods were used for correlation analysis, and the linear regression line was added to the figure. Statistical significance was defined at PϽ0.05; however, because of multiple comparisons of biomarkers levels, we applied the Bonferroni adjustment and used PϽ0.004 as significant for the data for biomarkers levels.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Patients were divided into 2 groups according to the presence or absence of mild coronary disease: early atherosclerosis (nϭ15) and control subjects (no evidence of atherosclerosis, nϭ15). No difference existed in the referring diagnosis between groups. The clinical characteristics of the 2 groups are outlined in Table 1 . Patients with early atherosclerosis were older than control subjects. No other significant differences existed in the clinical characteristics, including hyperlipidemia and use of statins, between the 2 groups. Impor-tantly, with regard to Lp-PLA 2 levels, the LDL cholesterol levels were similar in both groups. Lipoprotein(a) levels were slightly but nonsignificantly higher in patients with early atherosclerosis.
Hemodynamic data are presented in Table 2 . Hemodynamic parameters, including coronary blood flow and coronary flow reserve to adenosine, were similar in both groups.
Circulating and coronary sinus levels, gradients between the coronary sinus and arterial levels, and net production in the coronary circulation of Lp-PLA 2 , lysoPC, and CRP are outlined in Table 3 . No significant differences existed between the early atherosclerosis group and control group in either the arterial levels or the coronary sinus levels of Lp-PLA 2 and CRP. LysoPC levels in the coronary sinus were significantly lower in control subjects compared with both its arterial levels and its sinus levels in patients with early atherosclerosis. Furthermore, in patients with early atherosclerosis, Lp-PLA 2 levels in the coronary sinus were significantly higher compared with arterial levels, and a significant net production of Lp-PLA 2 in the coronary circulation was observed. LysoPC was produced in the coronary circulation in patients with early atherosclerosis and extracted in control subjects. Significant direct correlations existed in all patients between the gradients of Lp-PLA 2 and CRP (r s ϭ0.48, Pϭ0.007) and net production of both (r s ϭ0.49, Pϭ0.005).
Relationship Between Lp-PLA 2 and Atherosclerosis
The IVUS characteristics of the population are presented in Table 2 . Patients with early atherosclerosis had slightly but nonsignificantly increased vessel volume and decreased lumen volume, both features of remodeling. Coronary percent atheroma volume and plaque plus media volume were significantly larger in patients with early atherosclerosis. A positive correlation existed between plaque volume and Lp-PLA 2 gradient (r s ϭ0.36, PϽ0.05) and CRP gradient (r s ϭ0.37, Pϭ0.04). Percent atheroma volume also correlated with Lp-PLA 2 gradient (r s ϭ0.39, Pϭ0.03) and production (rϭ0.46, Pϭ0.01; r s ϭ0.37, Pϭ0.04; Figure 1 ). In addition, 
Relationship With Endothelial Dysfunction and LysoPC
A positive correlation existed between percent atheroma volume and lysoPC levels in the coronary sinus (r s ϭ0.43, Pϭ0.02) or the production of lysoPC in the coronary circulation (r s ϭ0.36, PϽ0.05). Because lysoPC may affect endothelial function, we also divided the patients into 2 groups according to the presence or absence of epicardial endothelial dysfunction (decrease in coronary artery diameter in response to acetylcholine). LysoPC gradients and net production in patients with and without endothelial dysfunction were 2 ng/mL (IQR, Ϫ16 to 11 ng/mL) versus Ϫ17 ng/mL (IQR, Ϫ30 to Ϫ10 ng/mL; Pϭ0.01) and 87 ng/min (IQR, Ϫ609 to 427 ng/min) versus Ϫ590 ng/min (IQR, Ϫ959 to Ϫ282 ng/min; Pϭ0.03), respectively. LysoPC net production also correlated with the degree of coronary artery diameter response to acetylcholine (Figure 2) . A trend was noted toward higher degree of endothelial dysfunction (epicardial and microvascular) with larger atheroma volume. No direct correlation existed between endothelial dysfunction and the production of Lp-PLA 2 or between the production of lysoPC and the coronary blood flow response to acetylcholine (a parameter of microvascular endothelial dysfunction).
Discussion
The present study demonstrates for the first time that early coronary atherosclerosis in humans is associated with local coronary production of Lp-PLA 2 and lysoPC. The production of Lp-PLA 2 across the coronary circulation significantly correlated with the degree of coronary atherosclerosis, whereas the production of its product lysoPC also correlated with coronary endothelial dysfunction. These observations support a role for Lp-PLA 2 as a participant in regional Figure 1 . Correlation between Lp-PLA 2 net production in the left anterior descending artery territory and percent atheroma volume.
Figure 2.
Correlation between lysoPC net production in the left anterior descending artery territory and endothelial dysfunction (coronary artery diameter response [⌬CAD] to acetylcholine).
vascular inflammation and endothelial dysfunction in early atherosclerosis in humans. A growing body of epidemiological studies reports an association between systemic Lp-PLA 2 levels and cardiovascular events. 11, [32] [33] [34] In a nested case-control study from the West of Scotland Coronary Prevention Study (WOSCOPS), the risk for coronary events in the highest quintile for Lp-PLA 2 was twice the risk for the lowest quintile. The risk was not attenuated after adjustment for other risk factors, including CRP. 11 In the Atherosclerosis Risk in Communities (ARIC) study, in a large cohort of middle-aged men and women, Lp-PLA 2 levels were associated with increased risk for incident coronary heart disease. 32 These associations raise the question of whether Lp-PLA2 is a marker of or plays an active role in the atherosclerotic process. The independent association between Lp-PLA 2 levels and cardiovascular risk among different populations and across different levels of cholesterol supports the hypothesis that Lp-PLA 2 has a causative role in this process. Further support for the role of Lp-PLA 2 early in the atherosclerotic process comes from the observation that Lp-PLA 2 levels are elevated in patients with subclinical coronary disease and coronary calcifications 35 and from a recent report from our group demonstrating that circulating Lp-PLA 2 is an independent predictor of coronary endothelial dysfunction, an established stage of early coronary atherosclerosis. 10 The present study extends these previous observations and demonstrates that in patients with minimal coronary atherosclerosis, local net production of Lp-PLA 2 is increased compared with patients without evidence of atherosclerosis as assessed by IVUS. We prospectively included all patients before performing the IVUS, which was done at the end of the protocol. It is likely that using stricter IVUS criteria to define the control subjects and comparing them with patients with atherosclerosis would result in even more robust results. We also were able to quantify the percent atheroma volume by 3-dimensional volumetric method. This established approach 31 enabled us to correlate the level of Lp-PLA 2 net production in the coronary circulation with the atheroma volume, and indeed a direct and significant association between these parameters was found.
The current paradigm is that Lp-PLA 2 is a promoter of vascular inflammation by virtue of generation of oxidized free fatty acids. 36 Initially, Lp-PLA 2 is carried by LDL to lesion-prone segments of the arterial wall. After LDL oxidation, enzymatic hydrolysis by Lp-PLA 2 leads to generation of lysoPC and oxidized nonesterified fatty acids that play a role in homing of inflammatory cells to lesion-prone areas. These inflammatory cells increase the concentration of Lp-PLA 2 in the vessel wall, upregulate intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and lead to oxidative stress and endothelial dysfunction. 37 Thus, the source of Lp-PLA 2 in the atherosclerotic plaque may be both from the circulation, bound to LDL, and from synthesis by inflammatory cells within the plaque. 12 The finding in the present study of increased production of lysoPC in the coronary circulation in patients with early atherosclerosis adds support to the aforementioned paradigm. LysoPC plays an important part in the effect of Lp-PLA 2 on endothelial dysfunction 14 ; indeed, we found a direct relationship between lysoPC net production and epicardial coronary endothelial function. The absence of correlation between microvascular endothelial dysfunction and lysoPC production may support the concept that the PLA 2 pathway may play a more significant role in the progression and complications of the epicardial vessels. Possible mechanisms by which lysoPC may affect endothelial function include downregulation of endothelial nitric oxide synthase mRNA expression and depletion of nitric oxide, 16 enhanced production of reactive oxygen species and oxidative stress 15 ; induction of endothelial cell apoptosis; and blocking of the repair mechanism by inhibition of endothelial cell migration to sites of endothelial damage. 17, 38 We hypothesize that in areas with increased local oxidative stress and vascular inflammation, an increase in the local production of Lp-PLA 2 will also be found. This process leads to the initiation and progression of atherosclerotic plaque. The local production of lysoPC causes endothelial dysfunction and further enhances vascular inflammation and progression of atherosclerosis.
Interestingly, patients without evidence of atherosclerosis had a reduction in Lp-PLA 2 and lysoPC levels in the coronary sinus compared with the arterial levels and a negative net production of these inflammatory mediators in the coronary circulation. It may be speculated that one of the functions of the normal vessel wall is extraction of substances like Lp-PLA 2 , lysoPC, and CRP, and with the development of atherosclerosis, a shift occurs from extraction to production of such substances.
Although we found a correlation between the gradients of Lp-PLA 2 and CRP across the coronary circulation, CRP gradients were similar in patients with early atherosclerosis and control subjects. In contrast, Lp-PLA 2 gradients and net production, and its product lysoPC, were significantly increased in patients with early atherosclerosis. Although CRP is a marker of systemic inflammation and is produced mainly in the liver, Lp-PLA 2 may be more directly related to local vascular inflammation and endothelial dysfunction. 36 These differences suggest that Lp-PLA 2 and CRP may have different pathophysiological mechanisms in the atherosclerotic process. 20, 36 Although Lp-PLA 2 is more associated with vascular inflammation, both Lp-PLA 2 and CRP can mediate increased expression of adhesion molecules and promote vascular inflammation. 39 The positive correlation between CRP and Lp-PLA 2 production in the present study may be consistent with the synergism between these 2 inflammatory mediators and is supported by findings from the ARIC study, which show that patients who had both CRP and Lp-PLA 2 in the highest tertiles had the highest risk for future coronary events 32 and stroke. 40 Our study is unique in the measurement of Lp-PLA 2 and lysoPC across an area of atherosclerosis. With this approach, variables that affect their levels such as gender and LDL levels do not affect the gradient. This approach enabled us to show that the activity of Lp-PLA 2 and lysoPC is associated with coronary endothelial function and the degree of the atherosclerotic process.
Study Limitations and Clinical Perspectives
The sampling from the coronary sinus was not selective. However, because none of the patients had significant atherosclerosis, we assumed similar levels in the coronary sinus tributaries for the calculations of net production. Although the mechanism of increased net production of Lp-PLA 2 in patients with early atherosclerosis is not completely understood, our findings have important clinical implications. Although intensive therapy with statins decreases both cholesterol levels and inflammation, it does not fully eliminate cardiovascular events. 41 Atherosclerosis has been considered an inflammatory disease for the past several years; thus, antiinflammatory agents are being tested for the prevention and treatment of coronary artery disease. 42 Drugs that inhibit the Lp-PLA 2 pathway may be more specific for atherosclerosis by decreasing oxidative stress and vascular inflammation and potentially will further decrease the risk for future cardiovascular events. Inhibitors of Lp-PLA 2 have been developed 43 and are currently being assessed in clinical trials. These inhibitors may potentially have a role in the treatment of patients with early atherosclerosis.
Conclusions
The present study demonstrates for the first time that humans with early coronary atherosclerosis and endothelial dysfunction are characterized by local coronary production of Lp-PLA 2 and lysoPC and supports the role of local oxidative stress and inflammation in early atherosclerosis in humans.
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